Skip to main content
CKD Bio Corp. logo

CKD Bio Corp. — Investor Relations & Filings

Ticker · 063160 ISIN · KR7063160006 LEI · 988400RFJ8DLB1NTOE10 KO Manufacturing
Open in API
Filings indexed 146 across all filing types
Latest filing 2022-03-04 AGM Information
Country KR South Korea
Listing KO 063160

About CKD Bio Corp.

https://www.ckdbio.com/en/home

CKD Bio Corp. is a pharmaceutical company specializing in fermentation and chemical synthesis technologies. The company develops and manufactures a range of products, including Active Pharmaceutical Ingredients (APIs), intermediates, and probiotics. Its API portfolio features fermentation-based products such as antibiotics, ß-lactamase inhibitors, and immunosuppressants. Leveraging extensive experience in fermentation, CKD Bio also produces next-generation probiotics using patented technology. Additionally, the company provides Contract Manufacturing (CMO) and Contract Research (CRO) services for APIs and intermediates, utilizing its cGMP-certified production facilities.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Chong Kun Dang Bio. It outlines the date, location, and agenda items (such as financial statement approval, articles of incorporation changes, and director compensation). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-03-04 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Chong Kun Dang Bio regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, and the date of the board resolution. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2022-03-04 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Chong Kun Dang Bio regarding the submission of an Investigational New Drug (IND) application for a Phase 1 clinical trial. It details the clinical trial design, objectives, and regulatory submission date to the Ministry of Food and Drug Safety. Since this is a specific regulatory announcement regarding business operations and clinical trial status that does not fit into categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-02-25 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Chong Kun Dang Bio regarding the approval of a pharmaceutical product (Tyemvers) for export. It is a 'Major Management Matter' disclosure filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or share repurchases, and serves as a general regulatory disclosure of a material business event, it is classified as a Regulatory Filing (RNS).
2022-02-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Chong Kun Dang Bio) announcing a significant change in revenue or profit/loss structure (30% or more). This is a standard preliminary financial disclosure required by the Korea Exchange (KRX) when there is a material change in financial performance before the final audit report is filed. Since it provides key financial highlights (revenue, operating profit, net income) and explains the reasons for the change, it fits the definition of an Earnings Release (ER), which covers initial announcements of periodic financial results. FY 2021
2022-01-28 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Chong Kun Dang Bio regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing a supply contract for 'Tyemvers' (Botulinum toxin type A) with CUTIA THERAPEUTICS. It details the contract terms, milestones, and financial impact. Since it is a specific regulatory disclosure of a material business event that does not fit into categories like M&A, dividends, or share issues, it is classified as a general Regulatory Filing (RNS).
2022-01-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.